The Scientific Challenge: Protein Misfolding

Proteins must fold into precise three-dimensional conformations to perform their biological functions. Genetic mutations often result in proteins that are structurally unstable or "misfolded."

Even if a misfolded protein retains its catalytic or functional potential, the cell's quality control machinery (such as the endoplasmic reticulum) typically recognizes it as defective and targets it for premature degradation. This leads to a loss-of-function pathology. Alternatively, misfolded proteins can escape degradation and aggregate, causing toxic gain-of-function pathologies, which are hallmarks of neurodegenerative diseases.

Traditionally, finding small molecules that can bind to these unstable proteins and correct their shapeâ??known as pharmacological chaperonesâ??has been exceptionally difficult. Traditional drug discovery relies on static protein structures, whereas misfolded proteins are highly dynamic and unstable, making target pockets elusive to standard screening technologies.

Core Technology: The ReSLa Platform

Congruence Therapeutics addresses the challenge of protein dynamics through its proprietary computational engine, ReSLa (Responsive Structure-Based Ligand Design).

Instead of treating proteins as rigid, static structures, the ReSLa platform models proteins as dynamic systems. The platform combines several advanced methodologies:

• Molecular Dynamics (MD) Simulations: ReSLa simulates the physical movements of atoms and molecules over time, mapping the conformational landscape of both wild-type and mutated proteins. This reveals transient, druggable pockets that do not appear in static X-ray crystallography or cryo-EM structures.
• Machine Learning and Artificial Intelligence: AI algorithms are trained on vast datasets of protein dynamics and chemical libraries. These models predict how specific mutations alter protein stability and identify chemical scaffolds likely to act as stabilizers.
• Biophysical Validation: Virtual hits generated by ReSLa are rapidly synthesized and validated using in vitro biophysical and biochemical assays to measure direct binding, thermal stabilization, and functional rescue of the target protein.

By using ReSLa, Congruence can design highly selective pharmacological chaperones that fit into specific, mutation-induced pockets, stabilizing the protein in its active conformation and allowing it to escape cellular degradation.

Products and Pipeline Focus

Congruence Therapeutics is developing an internal pipeline of small molecule stabilizers. The companyâ??s therapeutic focus is split between rare diseases and larger indications with shared pathology:

1. Lysosomal Storage Diseases (LSDs)

LSDs are a group of inherited metabolic disorders characterized by an abnormal build-up of various toxic materials in the body's cells as a result of enzyme deficiencies. Many of these deficiencies are caused by single-point mutations that lead to enzyme misfolding. * Gaucher Disease: Congruence is developing chaperones for acid beta-glucosidase (GBA1). Mutations in the GBA1 gene cause Gaucher disease, leading to accumulation of glucosylceramide. Correcting the folding of GBA1 restores enzymatic activity in the lysosome. * Other Rare Monogenic Diseases: The company is actively targeting other undisclosed lysosomal enzymes where stabilizing the mutated protein can restore sufficient baseline activity to alleviate clinical symptoms.

2. Neurodegenerative Diseases

Protein misfolding is a central driver in neurodegeneration. Congruence is applying its platform to discover brain-penetrant small molecules for: * GBA1-Associated Parkinson's Disease: Mutations in the GBA1 gene are the most common genetic risk factor for Parkinson's disease. Misfolded GBA1 leads to lysosomal dysfunction and the accumulation of alpha-synuclein aggregates. Congruenceâ??s GBA1 chaperones are designed to cross the blood-brain barrier, restore lysosomal clearance, and mitigate neurodegeneration.

Services and Collaboration Model

While Congruence focuses heavily on building its proprietary pipeline, its unique platform is designed for scalability and partnerships:

• Target Co-Development Partnerships: Congruence collaborates with pharmaceutical partners to apply the ReSLa platform to "undruggable" or highly unstable protein targets outside of its core therapeutic focus area (e.g., oncology or cardiovascular disease).
• In-Silico Screening Services: The company can rapidly screen external chemical libraries against dynamic protein models to identify novel binding pockets and optimize lead compounds for collaborators.

Corporate History, Leadership, and Funding

Congruence Therapeutics was founded by Dr. Clarissa Desjardins, an experienced biotechnology entrepreneur who previously founded Clementia Pharmaceuticals (acquired by Ipsen for up to $1.31 billion in 2019). The leadership team comprises seasoned drug discovery executives with backgrounds in computational chemistry, biophysics, and translational medicine.

Key Milestones:

• Inception (2021): Established in Montreal, Quebec, leveraging Canada's robust AI and deep-tech ecosystem.
• Series A Financing (2022): Congruence raised $35 million USD in a Series A funding round. The round was led by Amplitude Ventures, with participation from major life science investors including Lumira Ventures, SPDG, FTQ (Fonds de solidarité FTQ), Orbimed, and Driehaus Capital Management.
• Platform Expansion: The funding has been used to scale the ReSLa platform, build out wet-lab validation capabilities in Montreal, and advance their lead GBA1 program toward candidate selection.